Risankizumab for the Treatment of the Patients with Moderate to Severe Plaque Psoriasis During a 24-Week Period: Real-Life Experience

CONCLUSION: Risankizumab is an effective treatment option for both biologic naive or non-naive patients with or without comorbidities. However, long-term studies, including more extensive patient series, are needed to validate its efficacy and safety in real-life clinical settings.PMID:38144154 | PMC:PMC10749096 | DOI:10.2147/CCID.S442427

Source: Clinical, Cosmetic and Investigational Dermatology - December 25, 2023 Category: Dermatology Authors: Melis G önülal Didem Didar Balc ı Serap Öztürkcan Source Type: research